Fig. 2.

Combination of AZD5363 or NVP‐BEZ235 sensitizes cells to cisplatin and doxorubicin. (A) Cell lines were treated with increasing concentration of cisplatin (0–80 μm) or doxorubicin (0–8 μm) in the presence or absence of either AZD5363 (20 μm) or NVP‐BEZ‐235 (1 μm) for 24 h. MTT assays were then used to determine changes in cell viability. (B) Cell lines were treated with equal concentration of NVP‐BEZ235 or AZD5363 (5 μm). Western blot was performed using relevant antibodies, and β‐actin was used as a loading control. One‐way ANOVA followed by Tukey's post hoc test was performed. All data are means ± SEM of three independent experiments. *P < 0.05. [Colour figure can be viewed at wileyonlinelibrary.com]